These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 30104668)

  • 1. Biomaterial-assisted targeted modulation of immune cells in cancer treatment.
    Wang H; Mooney DJ
    Nat Mater; 2018 Sep; 17(9):761-772. PubMed ID: 30104668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Bionanomaterials in Tumor Immune Microenvironment Therapy.
    Wang J; Bao Y; Yao Y
    J Immunol Res; 2021; 2021():6663035. PubMed ID: 33628850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomaterials as Local Niches for Immunomodulation.
    Adu-Berchie K; Mooney DJ
    Acc Chem Res; 2020 Sep; 53(9):1749-1760. PubMed ID: 32786230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy.
    Han S; Huang K; Gu Z; Wu J
    Nanoscale; 2020 Jan; 12(2):413-436. PubMed ID: 31829394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Situ Modification of the Tumor Cell Surface with Immunomodulating Nanoparticles for Effective Suppression of Tumor Growth in Mice.
    Zheng C; Wang Q; Wang Y; Zhao X; Gao K; Liu Q; Zhao Y; Zhang Z; Zheng Y; Cao J; Chen H; Shi L; Kang C; Liu Y; Lu Y
    Adv Mater; 2019 Aug; 31(32):e1902542. PubMed ID: 31183900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomaterial-assisted photoimmunotherapy for cancer.
    Chen M; Chen Q
    Biomater Sci; 2020 Nov; 8(21):5846-5858. PubMed ID: 33016276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mn complex-mediated enhancement of antitumor response through modulating myeloid-derived suppressor cells in drug-resistant tumor.
    Das S; Banerjee K; Roy S; Majumder S; Chatterjee M; Majumdar S; Choudhuri SK
    In Vivo; 2014; 28(5):909-18. PubMed ID: 25189907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers.
    Siegler EL; Kim YJ; Chen X; Siriwon N; Mac J; Rohrs JA; Bryson PD; Wang P
    Mol Ther; 2017 Dec; 25(12):2607-2619. PubMed ID: 28919377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives.
    Cadete A; Alonso MJ
    Nanomedicine (Lond); 2016 Sep; 11(17):2341-57. PubMed ID: 27526874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune signatures predicting responses to immunomodulatory antibody therapy.
    Pawelec G
    Curr Opin Immunol; 2018 Apr; 51():91-96. PubMed ID: 29550661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory Nanomedicine.
    Bartneck M
    Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28383783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymeric micro- and nanoparticles for immune modulation.
    Ben-Akiva E; Est Witte S; Meyer RA; Rhodes KR; Green JJ
    Biomater Sci; 2018 Dec; 7(1):14-30. PubMed ID: 30418444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivering safer immunotherapies for cancer.
    Milling L; Zhang Y; Irvine DJ
    Adv Drug Deliv Rev; 2017 May; 114():79-101. PubMed ID: 28545888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
    Chmielewski M; Hombach AA; Abken H
    Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.
    Sha HH; Wang DD; Yan DL; Hu Y; Yang SJ; Liu SW; Feng JF
    Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28053197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving Cancer Immunotherapy Outcomes Using Biomaterials.
    Yan S; Luo Z; Li Z; Wang Y; Tao J; Gong C; Liu X
    Angew Chem Int Ed Engl; 2020 Sep; 59(40):17332-17343. PubMed ID: 32297434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunopathogenesis and immunotherapy of multiple myeloma.
    Tamura H
    Int J Hematol; 2018 Mar; 107(3):278-285. PubMed ID: 29368256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook.
    Wang C; Ye Y; Hu Q; Bellotti A; Gu Z
    Adv Mater; 2017 Aug; 29(29):. PubMed ID: 28556553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors as immunomodulators in cancer therapeutics.
    Shen L; Orillion A; Pili R
    Epigenomics; 2016 Mar; 8(3):415-28. PubMed ID: 26950532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.